These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16732128)

  • 1. Perinatal diagnosis of malignant hyperthermia susceptibility.
    Girard T; Jöhr M; Schaefer C; Urwyler A
    Anesthesiology; 2006 Jun; 104(6):1353-4. PubMed ID: 16732128
    [No Abstract]   [Full Text] [Related]  

  • 2. Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia.
    Urwyler A; Halsall PJ; Mueller C; Robinson R
    Acta Anaesthesiol Scand; 2003 Apr; 47(4):492; author reply 493. PubMed ID: 12694155
    [No Abstract]   [Full Text] [Related]  

  • 3. Continued progress in understanding the molecular genetics of malignant hyperthermia.
    Rosenberg H
    Can J Anaesth; 2011 Jun; 58(6):489-93. PubMed ID: 21455644
    [No Abstract]   [Full Text] [Related]  

  • 4. Definitive diagnosis of malignant hyperthermia susceptibility by genetic testing: A case report.
    Basile E; McGrath K; Jones K; Apostolov BD; Kahana M
    Paediatr Anaesth; 2023 Oct; 33(10):868-869. PubMed ID: 37357724
    [No Abstract]   [Full Text] [Related]  

  • 5. XXIVth Annual Meeting of the European Malignant Hyperthermia Group.
    Brandom BW; Muldoon SM
    Anesthesiology; 2005 Dec; 103(6):1324. PubMed ID: 16306761
    [No Abstract]   [Full Text] [Related]  

  • 6. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.
    Urwyler A; Deufel T; McCarthy T; West S;
    Br J Anaesth; 2001 Feb; 86(2):283-7. PubMed ID: 11573677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practicality and need for genetic testing for malignant hyperthermia.
    Brandom BW; Muldoon SM
    Anesthesiology; 2005 Nov; 103(5):1100; author reply 1101. PubMed ID: 16249688
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces?
    Mathews KD; Moore SA
    Arch Neurol; 2004 Jan; 61(1):27-9. PubMed ID: 14732615
    [No Abstract]   [Full Text] [Related]  

  • 9. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignant hyperthermia genetic testing in North America Working Group Meeting. Bethesda, Maryland. September 4-5, 2002.
    Sei Y; Sambuughin N; Muldoon S
    Anesthesiology; 2004 Feb; 100(2):464-5. PubMed ID: 14870754
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular genetic testing to diagnose malignant hyperthermia susceptibility.
    Girard T; Litman RS
    J Clin Anesth; 2008 May; 20(3):161-3. PubMed ID: 18502356
    [No Abstract]   [Full Text] [Related]  

  • 12. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
    MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
    J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetics of malignant hyperthermia.
    Brandom BW
    Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 15. Myopathic changes in malignant hyperthermia-susceptible patients.
    Rosenberg H
    Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
    [No Abstract]   [Full Text] [Related]  

  • 16. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.
    Riazi S; Kraeva N; Hopkins PM
    Anesthesiology; 2018 Jan; 128(1):168-180. PubMed ID: 28902675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Malignant hyperthermia--a hereditary and potentially life-threatening condition].
    Haugen T; Toft M; Müller CR; Aasly J
    Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2792-4. PubMed ID: 16244682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital ptosis, scoliosis, and malignant hyperthermia susceptibility in siblings with recessive RYR1 mutations.
    AlBakri A; Karaoui M; Alkuraya FS; Khan AO
    J AAPOS; 2015 Dec; 19(6):577-9. PubMed ID: 26691049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
    Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.